Latest & greatest articles for type 1 diabetes

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on type 1 diabetes or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on type 1 diabetes and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for type 1 diabetes

1881. Dietary patterns and risk for type 2 diabetes mellitus in U.S. men.

Dietary patterns and risk for type 2 diabetes mellitus in U.S. men. BACKGROUND: The role of diet in the development of type 2 diabetes mellitus remains unsettled. OBJECTIVE: To examine the association between major dietary patterns and risk for type 2 diabetes mellitus. DESIGN: Prospective cohort study. SETTING: United States. PARTICIPANTS: 42 504 male health professionals, 40 to 75 years of age, without diagnosed diabetes, cardiovascular disease, or cancer at baseline. MEASUREMENTS: Using (...) ), physical activity, and cigarette smoking. RESULTS: During 12 years of follow-up (466 508 person-years), we documented 1321 cases of type 2 diabetes. The prudent dietary pattern score was associated with a modestly lower risk for type 2 diabetes (relative risk for extreme quintiles, 0.84 [CI, 0.70 to 1.00]). In contrast, the western dietary pattern score was associated with an increased risk for type 2 diabetes (relative risk, 1.59 [CI, 1.32 to 1.93]; P < 0.001 for trend). A high score

Annals of Internal Medicine2002

1882. Oral antihyperglycemic therapy for type 2 diabetes: scientific review.

Oral antihyperglycemic therapy for type 2 diabetes: scientific review. CONTEXT: Care of patients with type 2 diabetes has been revolutionized throughout the past several years-first, by the realization of the importance of tight glycemic control in forestalling complications, and second, by the availability of several unique classes of oral antidiabetic agents. Deciphering which agent to use in certain clinical situations is a new dilemma facing the primary care physician. OBJECTIVE (...) : To systematically review available data from the literature regarding the efficacy of oral antidiabetic agents, both as monotherapy and in combination. DATA SOURCES: A MEDLINE search was performed to identify all English-language reports of unique, randomized controlled clinical trials involving recently available oral agents for type 2 diabetes. Bibliographies were also reviewed to find additional reports not otherwise identified. STUDY SELECTION AND DATA EXTRACTION: Studies (63) were included in the analysis

JAMA2002

1883. Oral antihyperglycemic therapy for type 2 diabetes: clinical applications.

Oral antihyperglycemic therapy for type 2 diabetes: clinical applications. Oral agents are the mainstay of pharmacologic treatment for type 2 diabetes, and physicians now have a number of agents to choose from. However, more choices translate into more complex decision making. Many patients with diabetes have associated comorbidities, and most diabetic patients will require more than 1 agent to achieve good glycemic control. This article illustrates several of the pharmacologic approaches (...) to type 2 diabetes through 4 situations that use principles of evidence-based medicine. The scenarios also highlight some of the difficulties in choosing the optimal pharmacologic treatment regimen for individual patients. Physicians should also recognize that type 2 diabetes is a multisystem disorder that requires multidisciplinary care, including education and ongoing counseling for effective patient self-management of the disease. Finally, patient preferences are a vital component of informed decision making

JAMA2002

1884. Resistin, central obesity, and type 2 diabetes.

Resistin, central obesity, and type 2 diabetes. Resistin, an adipocyte-derived cytokine, causes insulin resistance and glucose intolerance in mice. We investigated whether resistin expression was higher in human abdominal adipose tissue than other adipose tissue depots. We extracted RNA from 32 adipose tissue samples (13 subcutaneous abdominal, seven omentum, six thigh, and six breast). Quantitative PCR was used to determine resistin mRNA expression. Resistin mRNA concentrations were similar (...) in both the subcutaneous abdominal and omental depots. The abdominal depots showed a 418% increase in resistin mRNA expression compared with the thigh. Increased resistin expression in abdominal fat could explain the increased risk of type 2 diabetes associated with central obesity.

Lancet2002

1885. Management of type II diabetes. Management of blood pressure and blood lipids

Management of type II diabetes. Management of blood pressure and blood lipids Management of type II diabetes. Management of blood pressure and blood lipids Management of type II diabetes. Management of blood pressure and blood lipids National Institute for Clinical Excellence Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation National Institute for Clinical (...) Excellence. Management of type II diabetes. Management of blood pressure and blood lipids. London: National Institute for Clinical Excellence (NICE) 2002: 44 Authors' objectives This guideline is one of a series of five guidelines on type 2 diabetes. The aim of these guidelines is to provide guidance about managing type 2 diabetes for people with diabetes and the whole range of clinical staff who work in primary and secondary care, in order to maximise the potential for reducing complications

Health Technology Assessment (HTA) Database.2002

1886. Management of type II diabetes. Management of blood glucose

Management of type II diabetes. Management of blood glucose Management of type II diabetes. Management of blood glucose Management of type II diabetes. Management of blood glucose National Institute for Clinical Excellence Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation National Institute for Clinical Excellence. Management of type II diabetes. Management (...) of blood glucose. London: National Institute for Clinical Excellence (NICE) 2002: 27 Authors' objectives This guideline is one of a series of five guidelines on type 2 diabetes. The aim of these guidelines is to provide guidance about managing type 2 diabetes for people with diabetes and the whole range of clinical staff who work in primary and secondary care, in order to maximise the potential for reducing complications and improving the quality of life of people with the disease. Project page URL

Health Technology Assessment (HTA) Database.2002

1887. Pancreatic islet transplantation for patients with type 1 diabetes mellitus

Pancreatic islet transplantation for patients with type 1 diabetes mellitus Pancreatic islet transplantation for patients with type 1 diabetes mellitus Pancreatic islet transplantation for patients with type 1 diabetes mellitus Institute for Clinical Systems Improvement Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institute for Clinical Systems Improvement (...) . Pancreatic islet transplantation for patients with type 1 diabetes mellitus. Bloomington MN: Institute for Clinical Systems Improvement (ICSI) 2002 Authors' objectives This review aims to assess the available evidence on the effectiveness of pancreatic islet transplantation for patients with type 1 diabetes mellitus. Authors' conclusions With respect to pancreatic islet transplantation for patients with type 1 diabetes mellitus, the ICSI Technology Assessment Committee finds: Pancreatic islet

Health Technology Assessment (HTA) Database.2002

1888. Organisation of services for diabetic retinopathy screening: HTA Advice 1: Organisation of services for diabetic retinopathy screening: Understanding HTBS Advice: Diabetic retinopathy screening in Scotland

Organisation of services for diabetic retinopathy screening: HTA Advice 1: Organisation of services for diabetic retinopathy screening: Understanding HTBS Advice: Diabetic retinopathy screening in Scotland Organisation of services for diabetic retinopathy screening: HTA Advice 1: Organisation of services for diabetic retinopathy screening: Understanding HTBS Advice: Diabetic retinopathy screening in Scotland Organisation of services for diabetic retinopathy screening: HTA Advice 1: Organisation (...) of services for diabetic retinopathy screening: Understanding HTBS Advice: Diabetic retinopathy screening in Scotland NHS Quality Improvement Scotland Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation NHS Quality Improvement Scotland. Organisation of services for diabetic retinopathy screening: HTA Advice 1: Organisation of services for diabetic

Health Technology Assessment (HTA) Database.2002

1889. Management of type II diabetes. Renal disease - prevention and early management - guideline

Management of type II diabetes. Renal disease - prevention and early management - guideline Management of type II diabetes. Renal disease - prevention and early management - guideline Management of type II diabetes. Renal disease - prevention and early management - guideline National Institute for Clinical Excellence Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database (...) . Citation National Institute for Clinical Excellence. Management of type II diabetes. Renal disease - prevention and early management - guideline. London: National Institute for Clinical Excellence (NICE) 2002: 16 Authors' objectives This guideline is one of a series of five guidelines on type 2 diabetes. The aim of these guidelines is to provide guidance about managing type 2 diabetes for people with diabetes and the whole range of clinical staff who work in primary and secondary care, in order

Health Technology Assessment (HTA) Database.2002

1890. Management of type II diabetes. Retinopathy - screening and early management - guideline

Management of type II diabetes. Retinopathy - screening and early management - guideline Management of type II diabetes. Retinopathy - screening and early management - guideline Management of type II diabetes. Retinopathy - screening and early management - guideline National Institute for Clinical Excellence Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation (...) National Institute for Clinical Excellence. Management of type II diabetes. Retinopathy - screening and early management - guideline. London: National Institute for Clinical Excellence (NICE) 2002: 15 Authors' objectives This guideline is one of a series of five guidelines on type 2 diabetes. The aim of these guidelines is to provide guidance about managing type 2 diabetes for people with diabetes and the whole range of clinical staff who work in primary and secondary care, in order to maximise

Health Technology Assessment (HTA) Database.2002

1891. Self-management education for adults with type 2 diabetes: a meta-analysis of the effect on glycemic control

of contact time over the range of 1 to 28 hours. There were insufficient data to assess the influence of psychosocial variables on GHb. Authors' conclusions Education in self-management improved GHb immediately after the intervention in patients with type 2 diabetes. In addition, increased contact time with patients decreased GHb. The results suggested there would be a decrease in GHb of 1% for every additional 23.6 hours of contact between the patient and educator. CRD commentary The review question (...) of related interest Clarke M, Oxman AD, editors. Cochrane Reviewers Handbook 4.1.1 [updated December 2000]. In: The Cochrane Library, Issue 1, 2000. Oxford: Update Software. Updated quarterly. Indexing Status Subject indexing assigned by NLM MeSH Adaptation, Psychological; Adult; Aged; Blood Glucose /metabolism; Databases, Factual; Diabetes Mellitus, Type 2 /physiopathology /psychology; Ethnic Groups; Health Knowledge, Attitudes, Practice; Health Personnel /classification; Humans; Life Style; Middle Aged

DARE.2002

1892. Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes: meta-analysis of randomised controlled trials

Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes: meta-analysis of randomised controlled trials Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes: meta-analysis of randomised controlled trials Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients (...) with type 1 diabetes: meta-analysis of randomised controlled trials Pickup J, Mattock M, Kerry S Authors' objectives To compare glycaemic control and insulin dosage in people with type 1 diabetes who are treated by continuous subcutaneous insulin infusion (insulin infusion pump therapy) or optimised insulin injections. Searching Published trials that met the inclusion criteria were identified by searching MEDLINE (from 1975 to 2000) and EMBASE (from 1980 to 2000) for literature on insulin infusion

DARE.2002

1893. Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes

Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes CDC Diabetes Cost-effectiveness Group Record Status This is a critical (...) abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Three interventions aimed at reducing the occurrence of Type 2 diabetes were considered: intensive glycaemic control (insulin or sulfonylurea therapy), intensified hypertension control (angiotensin

NHS Economic Evaluation Database.2002

1894. Health and economic effects of adding nateglinide to metformin to achieve dual control of glycosylated hemoglobin and postprandial glucose levels in a model of Type 2 diabetes mellitus

Health and economic effects of adding nateglinide to metformin to achieve dual control of glycosylated hemoglobin and postprandial glucose levels in a model of Type 2 diabetes mellitus Health and economic effects of adding nateglinide to metformin to achieve dual control of glycosylated hemoglobin and postprandial glucose levels in a model of Type 2 diabetes mellitus Health and economic effects of adding nateglinide to metformin to achieve dual control of glycosylated hemoglobin (...) and postprandial glucose levels in a model of Type 2 diabetes mellitus Salas M, Ward A, Caro J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Combination therapy with nateglinide and metformin was compared with metformin monotherapy

NHS Economic Evaluation Database.2002

1895. Lifestyle intervention by group care prevents deterioration of Type II diabetes: a 4-year randomized controlled clinical trial

of the effects of diabetes patient education. Diabetes Care 1986;9:1-10. Norris SL, Engelgau MM, Venkat Narayan KM. Effectiveness of self-management training in type 2 diabetes. A systematic review of randomized controlled trials. Diabetes Care 2001;24:561-87. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97:1837-47. Indexing Status Subject indexing assigned by NLM MeSH Adult; Aged; Aged, 80 (...) Lifestyle intervention by group care prevents deterioration of Type II diabetes: a 4-year randomized controlled clinical trial Lifestyle intervention by group care prevents deterioration of Type II diabetes: a 4-year randomized controlled clinical trial Lifestyle intervention by group care prevents deterioration of Type II diabetes: a 4-year randomized controlled clinical trial Trento M, Passera P, Bajardi M, Tomalino M, Grassi G, Borgo E, Donnola C, Cavallo F, Bondonio P, Porta M Record Status

NHS Economic Evaluation Database.2002

1896. A health economic model to assess the long-term effects and cost-effectiveness of orlistat in obese type 2 diabetic patients

. Hollander PA, Elbein SC, Hirsch IB, Kelley D, McGill J, Taylor T, et al. Role of orlistat in the treatment of obese patients with type 2 diabetes: a 1-year randomised double-blind study. Diabetes Care 1998;21:1288-94. Muls E, Kolanowski J, Scheen A, Van Gaal L. Efficacy of orlistat treatment in obese patients with hypercholesterolaemia (Abstract). European Congress on Obesity. International Journal of Obesity 2000;24:S97. United Kingdom Prospective Diabetes Study Group. Effect of intensive blood-glucose (...) A health economic model to assess the long-term effects and cost-effectiveness of orlistat in obese type 2 diabetic patients A health economic model to assess the long-term effects and cost-effectiveness of orlistat in obese type 2 diabetic patients A health economic model to assess the long-term effects and cost-effectiveness of orlistat in obese type 2 diabetic patients Lamotte M, Annemans L, Lefever A, Nechelput M, Masure J Record Status This is a critical abstract of an economic evaluation

NHS Economic Evaluation Database.2002

1897. Insulin pumps, conventional and intensive multiple injection insulin therapy for type 1 diabetes mellitus

Insulin pumps, conventional and intensive multiple injection insulin therapy for type 1 diabetes mellitus Insulin pumps, conventional and intensive multiple injection insulin therapy for type 1 diabetes mellitus Insulin pumps, conventional and intensive multiple injection insulin therapy for type 1 diabetes mellitus Oduneye F Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA (...) database. Citation Oduneye F. Insulin pumps, conventional and intensive multiple injection insulin therapy for type 1 diabetes mellitus. London: Bazian Ltd (Editors), Wessex Institute for Health Research and Development, University of Southampton 2002: 8 Authors' objectives This study aims to assess the effects of continuous insulin infusion pumps compared with multiple injection and conventional insulin therapy in people with type 1 diabetes mellitus. Authors' conclusions We found good evidence

Health Technology Assessment (HTA) Database.2002

1898. Implementing intensive control of blood glucose concentration and blood pressure in type 2 diabetes in England: cost analysis (UKPDS 63).

and blood pressure to all people with diagnosed type 2 diabetes in England is estimated to be pound 100.5m ($156m; euro;159m), which is equivalent to less than 1% of the proposed additional annual expenditure on the NHS in 2001-5. This estimate varied in sensitivity analyses from pound 67m to pound 121m. Policies to improve control of blood glucose and blood pressure of people with type 2 diabetes are effective in reducing complications associated with the disease and are also cost effective. The total (...) Implementing intensive control of blood glucose concentration and blood pressure in type 2 diabetes in England: cost analysis (UKPDS 63). 12386035 2002 10 18 2002 11 22 2014 06 11 1756-1833 325 7369 2002 Oct 19 BMJ (Clinical research ed.) BMJ Implementing intensive control of blood glucose concentration and blood pressure in type 2 diabetes in England: cost analysis (UKPDS 63). 860 To estimate the incremental cost of implementing policies for intensive control of blood glucose concentration

BMJ2002 Full Text: Link to full Text with Trip Pro

1899. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.

Evid Based Nurs. 2002 Oct;5(4):109 12402812 Med J Aust. 2003 Feb 17;178(4):180-1 12580748 Can Fam Physician. 2004 Mar;50:369-71 15318673 Adult Blood Glucose metabolism Body Mass Index Diabetes Mellitus, Type 2 epidemiology prevention & control Double-Blind Method Energy Intake Exercise Female Humans Hypoglycemic Agents adverse effects therapeutic use Incidence Life Style Male Metformin adverse effects therapeutic use Middle Aged Patient Compliance Risk Factors Weight Loss NIHMS5217 PMC1370926 2002 (...) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. 11832527 2002 02 08 2002 02 20 2016 10 25 1533-4406 346 6 2002 Feb 07 The New England journal of medicine N. Engl. J. Med. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. 393-403 Type 2 diabetes affects approximately 8 percent of adults in the United States. Some risk factors--elevated plasma glucose concentrations in the fasting state and after an oral glucose load

NEJM2002 Full Text: Link to full Text with Trip Pro

1900. Effects of insulin in relatives of patients with type 1 diabetes mellitus.

Effects of insulin in relatives of patients with type 1 diabetes mellitus. 12037147 2002 05 30 2002 06 05 2011 11 17 1533-4406 346 22 2002 May 30 The New England journal of medicine N. Engl. J. Med. Effects of insulin in relatives of patients with type 1 diabetes mellitus. 1685-91 It is unknown whether insulin therapy can delay or prevent diabetes in nondiabetic relatives of patients with diabetes. In a randomized, controlled, nonblinded clinical trial, we screened 84,228 first-degree (...) without ascertainment bias, was similar in the two groups. In persons at high risk for diabetes, insulin at the dosage used in this study does not delay or prevent type 1 diabetes. Diabetes Prevention Trial--Type 1 Diabetes Study Group eng Clinical Trial Journal Article Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S. United States N Engl J Med 0255562 0028-4793 0 Hypoglycemic Agents 0 Insulin AIM IM N Engl J Med. 2002 Oct 3;347(14

NEJM2002